Session » Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster I
-
Abstract Number: 1905
Stimulators of Soluble Guanylate Cyclase (sGC) Inhibit Experimental Skin Fibrosis of Different Aetiologies
-
Abstract Number: 1906
Stimulators of Soluble Guanylate Cyclase (sGC) Improve Wound Healing in the Tsk-1 Mouse Skin Fibrosis Mode
-
Abstract Number: 1907
Inhibition of Phosphodiesterase 4 (PDE4) Reduces Dermal Fibrosis By Interfering with the Release of Pro-Fibrotic Cytokines from M2-Macrophages
-
Abstract Number: 1908
Macitentan Responsiveness Supports the Validity of a Murine Model of Pulmonary Hypertension in Scleroderma Associated with Altered Tgfbeta/BMPR2 Signalling
-
Abstract Number: 1909
Nailfold Capillaroscopic Assessment and Vascular Biomarkers in Systemic Sclerosis: Low CD40L Levels in Patients with Late Scleroderma Patterns
-
Abstract Number: 1910
Increased Circulating CD204/CD206 Double Positive Monocyte/Macrophages in Systemic Sclerosis Patients with “Early” Capillaroscopic Pattern of Microvascular Damage
-
Abstract Number: 1911
Monocyte Chemoattractant Protein-1 (MCP-1, CCL2) Is a Potential Local Marker of Renal Involvement in Scleroderma
-
Abstract Number: 1912
Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Immune Abnormalities in Animal Models of Systemic Sclerosis
-
Abstract Number: 1913
Lysyl Oxidase Induces Fibrosis Via Upregulation of IL-6 and Serves As a Biomarker to Monitor Response to Therapy
-
Abstract Number: 1914
Oncostatin M As a Potential Molecular Target in Systemic Sclerosis
-
Abstract Number: 1915
Pathogenetic Overlap Between Localised and Systemic Scleroderma: A Study of Nodular and Keloidal Morphea Occurring in Systemic Sclerosis
-
Abstract Number: 1916
Validation of Novel Biomarker Candidates for Systemic Sclerosis
-
Abstract Number: 1917
Developing and Validating a Serum Biomarker for the Extent of Skin Disease in Patients with Diffuse Cutaneous Systemic Sclerosis
-
Abstract Number: 1918
Pharmacologic Targeting of Mitochondrial Dysfunction in Systemic Sclerosis: Enhanced SIRT3 Signaling
-
Abstract Number: 1919
Genetic Deletion of Toll-like Receptor 4 (Tlr4) Abrogates TGF-β1-Induced Endothelial-to-Mesenchymal Transition (EndoMT) in Murine Pulmonary Endothelial Cells
-
Abstract Number: 1921
Role of TLRs in the Abnormal Secretion of CXCL-4 By Plasmacytoid Dendritic Cells of Patients with Systemic Sclerosis
-
Abstract Number: 1922
Peripheral B Lymphocytes Secrete Both Interleukin 6 and Transforming Growth Factor-Beta and Potentiate Fibroblast Activation in Systemic Sclerosis
-
Abstract Number: 1923
The Role of Inflammatory Myeloid Cell Compartment in Myocardial Fibrogenesis and Remodelling in Systemic Sclerosis
-
Abstract Number: 1924
Increased Stat1 and Stat 1 Phosphorylation in Patients with Systemic Sclerosis (SSc)
-
Abstract Number: 1925
Interleukin-35 Is Upregulated in Systemic Sclerosis and Its Serum Levels Are Increased in Early Disease
-
Abstract Number: 1926
Wnt5a Activates Wnt/PCP-Signaling to Promote Fibroblast Activation and Fibrosis